Compare PANL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | IVVD |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.2M | 437.1M |
| IPO Year | 2015 | 2021 |
| Metric | PANL | IVVD |
|---|---|---|
| Price | $8.19 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $9.00 | $8.75 |
| AVG Volume (30 Days) | 475.9K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $385,088,209.00 | $53,426,000.00 |
| Revenue This Year | $0.72 | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | $39.48 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $4.27 | $0.49 |
| 52 Week High | $9.39 | $3.07 |
| Indicator | PANL | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 35.96 |
| Support Level | $7.99 | $1.11 |
| Resistance Level | $9.23 | $1.41 |
| Average True Range (ATR) | 0.40 | 0.12 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 56.49 | 19.35 |
Pangaea Logistics Solutions Ltd and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company's operating segments include the shipping segment: The Company's operating segments include the shipping segment and six terminal and stevedoring operating segments. The company operates in the USA, Germany, Canada, Singapore, the United Kingdom, and other countries, with maximum from the USA and others.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.